Next 10 |
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced t...
2024-04-19 08:16:20 ET Losers: Tritium DCFC Limited ( DCFC ) -59% . Nexalin Technology ( NXL ) -29% . Moolec Science ( MLEC ) -17% . AGBA Group Holding Limited ( AGBA ) -15% . INVO Bioscience ( INVO ) -11% . Iczoom Group ( ...
2024-04-18 10:00:26 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...
A look at the top 10 most actives in the United States Beneficient (BENF) rose 44.7% to $0.1 on volume of 79,601,246 shares PaxMedica Inc. (PXMD) rose 123.0% to $0.9183 on volume of 54,446,384 shares NextPlat Corp (NXPL) rose 40.0% to $2.1 on volume of 30,284,097 shares Direxion Daily S...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) fell 26.7% to $0.717 on volume of 293,193,103 shares PROSHARES TRUST (SQQQ) fell 4.6% to $10.4 on volume of 158,399,098 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.4% to $3.21 on volume o...
2024-04-11 12:55:33 ET More on Mid-day movers & stocks. Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru gets Na...
--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines fo...
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceut...
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announce...
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today ann...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing inn...
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced t...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...